Search clinical trials for: MK6592

Total 18 results

Vyne Therapeutics Inc.

Completed

Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

Overactive Bladder | Urinary Incontinence
Merck Sharp & Dohme LLC

Terminated

MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)

Alzheimer's Disease
Vyne Therapeutics Inc.

Terminated

A Study of MK0594 in Patients With Alcohol Dependence (0594-020)

Alcohol Dependence
Merck Sharp & Dohme LLC

Terminated

Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)

Advanced Solid Tumors
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)

Fungal Infection
Organon and Co

Completed

Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED) (BRAVO)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Approved for marketing

Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)

Mycoses
Merck Sharp & Dohme LLC

Completed

Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)

Fungal Infection | Neutropenia | Acute Myelogenous Leukemia
Merck Sharp & Dohme LLC

Completed

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

Invasive Aspergillosis

Belgium, United States, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Peru, Russian Federation
Merck Sharp & Dohme LLC

Completed

Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641)

Mycoses
M.D. Anderson Cancer Center
Schering-Plough

Completed

Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia

Leukemia | Fungal Infection

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)

Leukopenia
Merck Sharp & Dohme LLC

Completed

A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) (STOP CHAGAS)

Chagas Disease
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)

Fungal Infections
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

Invasive Pulmonary Aspergillosis | Fungal Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)

Onychomycosis
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)

Fungal Infections
M.D. Anderson Cancer Center

Completed

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic... and other conditions

United States

3

Subscribe